Zacks Research Predicts Reduced Earnings for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Zacks Research cut their Q4 2025 earnings estimates for shares of Gilead Sciences in a research report issued on Thursday, November 13th. Zacks Research analyst Team now expects that the biopharmaceutical company will earn $1.81 per share for the quarter, down from their prior estimate of $1.82. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences’ Q1 2026 earnings at $1.69 EPS, Q2 2026 earnings at $1.80 EPS, Q3 2026 earnings at $2.32 EPS, Q4 2026 earnings at $2.31 EPS, FY2026 earnings at $8.13 EPS, Q1 2027 earnings at $1.97 EPS, Q2 2027 earnings at $2.14 EPS, Q3 2027 earnings at $2.55 EPS and FY2027 earnings at $9.04 EPS.

Several other research analysts also recently commented on GILD. Daiwa Capital Markets increased their price objective on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Truist Financial reaffirmed a “buy” rating and set a $145.00 target price (up from $127.00) on shares of Gilead Sciences in a research note on Monday, November 3rd. Finally, Rothschild & Co Redburn increased their target price on shares of Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $129.13.

Gilead Sciences Stock Down 0.1%

GILD opened at $125.02 on Friday. The stock has a market capitalization of $155.11 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 0.81 and a beta of 0.32. Gilead Sciences has a fifty-two week low of $86.08 and a fifty-two week high of $127.68. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a fifty day moving average of $117.44 and a two-hundred day moving average of $112.83.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the prior year, the firm earned $2.02 EPS. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is 48.99%.

Insiders Place Their Bets

In related news, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the sale, the executive vice president directly owned 43,676 shares of the company’s stock, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 94,646 shares of company stock worth $11,311,286. 0.27% of the stock is currently owned by company insiders.

Institutional Trading of Gilead Sciences

Institutional investors have recently added to or reduced their stakes in the stock. Trivium Point Advisory LLC grew its stake in shares of Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after buying an additional 83 shares during the period. Binnacle Investments Inc boosted its holdings in Gilead Sciences by 11.8% in the third quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock worth $87,000 after acquiring an additional 83 shares in the last quarter. Rothschild Investment LLC grew its stake in Gilead Sciences by 1.9% in the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after acquiring an additional 84 shares during the period. Hemington Wealth Management grew its stake in Gilead Sciences by 9.3% in the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 85 shares during the period. Finally, Ignite Planners LLC increased its holdings in shares of Gilead Sciences by 1.1% during the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after acquiring an additional 86 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.